TOP TEN perturbations for 39343_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39343_at
Selected probe(set): 204658_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39343_at (204658_at) across 6674 perturbations tested by GENEVESTIGATOR:

kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):-2.6030827
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (8 week)
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.

glioma study 16 (LN-229) / normal astrocyte sample

Relative Expression (log2-ratio):2.310586
Number of Samples:2 / 3
Experimental glioma study 16 (LN-229)
Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue

Relative Expression (log2-ratio):1.9957819
Number of Samples:5 / 6
Experimental atopic dermatitis study 21 (lesional; whole skin)
Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal skin tissue
Full thickness skin samples isolated from healthy subjects by laser capture microdissection.

IgA nephropathy study 8 / control glomerulus tissue

Relative Expression (log2-ratio):1.9654169
Number of Samples:20 / 20
Experimental IgA nephropathy study 8
Hand-microdissected glomerular tissue samples derived from kidney biopsies of patients with IgA nephropathy (IgAN). Whole-core patient biopsies were obtained as part of routine renal biopsy procedures.
Control control glomerulus tissue
Hand-microdissected glomerular tissue samples derived from kidney biopsies of healthy living kidney transplant donors. The biopsies were taken after reperfusion in the kidney transplant recipient.

paracetamol (acetaminophen) study 7 (10000uM) / vehicle (DMSO) treated HepG2 sample

Relative Expression (log2-ratio):-1.9363508
Number of Samples:3 / 21
Experimental paracetamol (acetaminophen) study 7 (10000uM)
HepG2 cells treated with compound: paracetamol (10000uM; CAS no.:103-90-2) for 24 hours. Paracetamol is hepatotoxic and may cause necrosis. HepG2 cells were treated with the IC20 concentration measured after 24 hours. ATC code:
Control vehicle (DMSO) treated HepG2 sample
HepG2 cells treated with DMSO (0.5% v/v) as solvent control for 24 hours.

glioma study 16 (BS-149) / normal astrocyte sample

Relative Expression (log2-ratio):1.9212551
Number of Samples:2 / 3
Experimental glioma study 16 (BS-149)
Human glioma cell line BS149 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

glioma study 16 (LN-18) / normal astrocyte sample

Relative Expression (log2-ratio):1.855094
Number of Samples:2 / 3
Experimental glioma study 16 (LN-18)
Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

uterine/pelvic pathology study 2 (pro. MCP) / uterine/pelvic pathology study 2 (late se MCP)

Relative Expression (log2-ratio):-1.7438812
Number of Samples:15 / 2
Experimental uterine/pelvic pathology study 2 (pro. MCP)
Endometrial tissue samples collected from women with uterine/pelvic pathology in the proliferative menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.
Control uterine/pelvic pathology study 2 (late se MCP)
Endometrial tissue samples collected from women with uterine/pelvic pathology in the late secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.

pediatric septic shock study 3 (infant; subclass A) / normal blood sample (infant)

Relative Expression (log2-ratio):-1.6469135
Number of Samples:8 / 17
Experimental pediatric septic shock study 3 (infant; subclass A)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control normal blood sample (infant)
Whole blood samples from infants (1 month – 1 year). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study.

pediatric septic shock study 3 (school-age; subclass A) / normal blood sample (school-age)

Relative Expression (log2-ratio):-1.6357679
Number of Samples:6 / 9
Experimental pediatric septic shock study 3 (school-age; subclass A)
Whole blood samples obtained from school-age children (≥ 6 years) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Three children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control normal blood sample (school-age)
Whole blood samples from school-age children (≥ 6 years). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study.